Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HRS 6209

Next Previous
Drug Profile

HRS 6209

Alternative Names: HRS-6209

Latest Information Update: 03 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Developer Jiangsu Hengrui Medicine Co.; Shandong Suncadia Medicine
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Breast cancer
  • Phase I Solid tumours

Most Recent Events

  • 03 Jun 2026 HRS 6209 is still in phase I trials for Solid tumours (Late stage disease, Monotherapy) in China (NCT05781048)
  • 27 May 2026 Jiangsu HengRui Medicine plans a phase I bioavailability trial in healthy subjects in China (PO) in May 2026 (NCT07610148)
  • 15 May 2026 Atridia initiates a phase I trial for Breast cancer (Inoperable/unresectable, Late-stage diseases, Metastatic diseases, Combination therapy) (Parentral) (NCT07358377)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top